BIBR - 1048，勃林格殷格翰公司。

BIBR-1048 Boehringer Ingelheim.

作者信息

Mungall Dennis

机构信息

The Miami Project to Cure Paralysis, Department of Neurological Surgery, University of Miami School of Medicine, Lois Pope Life Center, FL 33101, USA.

出版信息

Curr Opin Investig Drugs. 2002 Jun;3(6):905-7.

PMID:12137410

Abstract

BIBR-1048, a thrombin inhibitor and an orally-active prodrug of BIBR-953ZW, is under development by Boehringer Ingelheim as a potential antithrombotic agent [331881]. By 1999, BIBR-1048 was in phase II clinical trials for thromboembolism and the prevention of stroke due to atrial fibrillation [331881]; by April 2002, proof-of-principle had been demonstrated in phase II trials in deep vein thrombosis [446554]. In July 2001, the company revealed that an IND was expected to be filed for BIBR-953ZW in 2002 [415884].

摘要

BIBR-1048是一种凝血酶抑制剂，也是BIBR-953ZW的口服活性前药，目前正由勃林格殷格翰公司作为一种潜在的抗血栓药物进行研发[331881]。到1999年时，BIBR-1048已进入用于治疗血栓栓塞和预防房颤所致中风的II期临床试验阶段[331881]；到2002年4月，其在深静脉血栓形成的II期试验中已证明了原理验证[446554]。2001年7月，该公司透露预计将在2002年为BIBR-953ZW提交一份研究性新药申请[415884]。